Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Targets Global Respiratory Biosimilars With Kemwell JV

Indian Firm Will Bring Its ‘Respiratory Prowess’ To Planned Venture

Executive Summary

Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.

You may also be interested in...



Cipla: $500m North American Sales Boost Possible In Five Years

Cipla’s recent US approval with a partner for its 505(b)(2) hybrid lanreotide injection product signaled the firm’s intentions to broaden in the peptides and injectables space, as it looks to add hundreds of millions to its revenue base by Cipla’s 2027 financial year.

Deal Watch: Lilly Teams Up With Lycia In Protein Degradation

Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.

Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV

Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel